Medical technology company Smith+Nephew (SN.L,SNN) announced Wednesday that it has entered into a definitive agreement to acquire CartiHeal for an initial cash consideration of $180 million at closing.Under the deal terms, Smith+Nephew will also pay up to a further $150 million contingent on financial performance.The acquisition is expected to close in the first quarter of 2024.

医疗技术公司Smith+Nephew（SN.L，SNN）星期三宣布，它已达成明确协议，收购CartiHeal，截止时初步现金考虑1.8亿美元。根据协议条款，Smith+Nephew还将根据财务业绩再支付1.5亿美元。该收购预计将于2024年第一季度结束。

Breakeven to trading profit is targeted by 2027. CartiHeal, founded in 2009 as a university spin-out, is the developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee.CartiHeal retains a small facility close to Tel Aviv and a sales office in New Jersey, US. Smith+Nephew noted that CartiHeal has large quantities of raw material in the US and, by close of the deal, will also have ample US stock to support full commercial launch.

交易利润的突破是2027年的目标。CartiHeal成立于2009年，是一所大学的分公司，是Agili-C的开发商，Agili-C是一种用于膝关节软骨再生的新型运动医学技术。CartiHeal保留了靠近特拉维夫的小型工厂和美国新泽西州的销售办公室.Smith+Nephew指出，CartiHeal在美国拥有大量原材料，并且在交易结束时，还将拥有充足的美国库存支持全面的商业发布。

All CartiHeal employees are expected to transfer to Smith+Nephew..

预计所有CartiHeal员工都会转到Smith+Nephew。。

Agili-C is a porous, biocompatible, and resorbable scaffold which promotes natural regeneration of the articular cartilage and restoration of its underlying subchondral bone. The U.S. Food and Drug Administration granted Agili-C Breakthrough Device designation status in 2020 and Premarket Approval or PMA in March 2022.The company noted that Agili-C is an off-the-shelf one-step treatment for osteochondral (bone and cartilage) lesions with a broader indication than existing treatments.Deepak Nath, Chief Executive Officer of Smith+Nephew said, 'The acquisition of this disruptive technology supports our strategy to invest behind our successful Sports Medicine business.

Agili-C是一种多孔，生物相容且可再吸收的支架，可促进关节软骨的自然再生和其下面的软骨下骨的恢复。美国食品和药物管理局于2020年授予Agili-C突破性设备指定状态，并于2022年3月获得上市前批准或PMA。该公司指出，Agili-C是骨软骨（骨和软骨）病变的现成一步治疗方法，其适应症比现有治疗方法更广。Smith+Nephew首席执行官Deepak Nath表示，“收购这项颠覆性技术支持我们投资于成功的运动医学业务的战略。

Agili-C's superior clinical performance makes it highly complementary to our existing knee repair portfolio and with our proven commercial expertise in high-growth biologics, we are confident that we will drive further success with this compelling treatment option.'The acquisition will be financed from existing cash and debt facilities.

Agili-C卓越的临床表现使其与我们现有的膝关节修复产品组合高度互补，并凭借我们在高生长生物制剂方面经过验证的商业专业知识，我们相信，通过这种引人注目的治疗方案，我们将取得进一步的成功收购将由现有的现金和债务设施提供资金。

For comments and feedback contact: editorial@rttnews.comBusiness News.

有关意见和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In November 2023

2023年11月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In October 2023

2023年10月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票